2nd GPCR-Targeted Drug Discovery Summit

Unlocking the Next Wave of Clinically Relevant GPCR Targets

Returning for the 2nd year, the GPCR-Targeted Drug Discovery Summit is the only industry-led meeting of its kind dedicated to congregating the most forward thinking biotechs, established large pharma, and key academic opinion leaders committed to discovering and validating the next wave of GPCR targets across a breadth of indications.

- Welcoming a whole host of exciting new GPCR-focused biotechs onto the agenda, with presentations from Septerna, Tectonic, DJS Antibodies, OKYO Pharma, and On Target Therapeutics

- Increased emphasis on allosteric modulation with 5 talks dedicated to highlighting novel methods of integrating this new ‘modality’ and the potential it holds as an alternative to agnostic and antagonistic targeting

- A brand-new workshop day featuring 3 workshops; workshop A on specific, lesser explored GPCR receptors (adhesion and chemokine) led by 2 key academic leaders, workshop B on allosteric modulation with 3 expert leaders, and workshop C, a deep dive into what venture capitalists are looking for in the GPCR space right now

… as well as covering the most pressing challenges in GPCR-target identification with integration of novel platforms, target validation with improvements being made in in-vitro assay kits, and predictive modelling enhancements made by machine learning and computational technologies.
The 2nd GPCR-Targeted Drug Discovery Summit will equip your team with the knowhow to tackle hurdles in the orphan drug space, elevate understanding of opportunity in dark targets, bias signalling, and the various modalities currently being pursued as novel GPCR drug candidates.

https://gpcrs-drugdiscovery.com/

February 21-23, 2023
Boston, MA

Contact:
[email protected]
Speakers: Graeme Milligan, Professor, University of Glasgow, Bryan Roth, Professor of Pharmacology, UNC School of Medicine, Jeff Finer, Chief Executive Officer, Septerna, Kate Lansu, Senior Scientist, Eli Lilly & Company, Laurent Sabbagh, Head of Biology, DOMAIN Therapeutics

Others Details

Brochure https://go.evvnt.com/1343409-0?pid=6581